Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02855580 · ClinicalTrials.gov registry record

Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic

A clinical trial of Anxiety and Major Depressive Disorder, sponsored by University of Florida.

Completed
Registry status
71
Enrollment target
1
Study location

NCT02855580: Completed study of Anxiety and Major Depressive Disorder, sponsored by University of Florida.

NCT02855580 is a study of Anxiety and Major Depressive Disorder that has completed, run by University of Florida. The registered enrollment target is 71 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (84% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02855580, a study of Anxiety and Major Depressive Disorder, has completed, sponsored by University of Florida.

COMPLETED
Registry status
71 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to examine the feasibility, acceptability, and utility of pharmacogenomic (PGX) testing (specifically for the cytochrome P450 2D6 and 2C19 genes) prior to initiating treatment with an antidepressant (AD) among children and adolescents in the University of Florida Child Psychiatry clinics.

Primary Outcome

The feasibility of pharmacogenomic (PGX) testing (specifically for the cytochrome P450 and 2C19 genes) prior to initiating treatment in a child and adolescent population will be measured through medication compliance and frequency of medication changes as described in the patient's medical record.

Study Locations (1)

Florida

  • Child Psychiatry Clinic at University of Florida - Gainesville

Trial Details

FieldValue
Enrollment Target 71 participants
Start Date 2016-09
Est. Completion 2017-07-06
University of Florida

1,106 total trials

What the finished NCT02855580 record still lists

NCT02855580 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 71 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (84% lower).

The record links to 3 conditions, with Anxiety appearing as the primary indexed condition, and to 0 interventions.

NCT02855580 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT02855580 about?

NCT02855580 is a clinical study titled "Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic". The purpose of this study is to examine the feasibility, acceptability, and utility of pharmacogenomic (PGX) testing (specifically for the cytochrome P450 2D6 and 2C19 genes) prior to initiating treatment with an antidepressant (AD) among children and adolescents in the University of Florida Child P...

What is the current status of trial NCT02855580?

This trial is currently completed. The enrollment target is 71 participants. The study started on 2016-09. Estimated completion is 2017-07-06.

What conditions does trial NCT02855580 study?

This clinical trial studies the following conditions: Anxiety, Major Depressive Disorder, Obsessive - Compulsive Disorder.

Who is sponsoring clinical trial NCT02855580?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02855580 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02855580's enrollment target sits among peer trials

71 212th of 364 higher than 151 of 364 other Anxiety trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05452889 · 71 participants · Early Phase 1

    PET Image in PAH Patients

  • NCT05766943 · 71 participants · NA

    Reduction of Myopotential Interference With Smart Pass in S-ICD Patients

  • NCT06229678 · 71 participants · Early Phase 1

    Ketones, SGLT2, HFrEF

  • NCT06377566 · 71 participants · Phase 2

    A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02855580, the US trial registry maintained by the National Library of Medicine. NCT02855580 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.